Yong Eun Jang

Mr. Yong Eun Jang

Ajou University, South Korea
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JHJi Su Hwang
Ji Su Hwang
SKSeok Gi Kim
Seok Gi Kim
TSTae Hwan Shin
Tae Hwan Shin
YJYong Eun Jang
Yong Eun Jang
DKDo Hyeon Kwon
Do Hyeon Kwon
GLGwang Lee
Gwang Lee
Cancer is a group of diseases causing abnormal cell growth, altering the genome, and invading or spreading to other parts of the body. Among therapeutic peptide drugs, anticancer peptides (ACPs) have been considered to target and kill cancer cells because cancer cells have unique characteristics such as a high negative charge and abundance of microvilli in the cell membrane when compared to a normal cell. ACPs have several advantages, such as high specificity, cost-effectiveness, low immunogenicity, minimal toxicity, and high tolerance under normal physiological conditions. However, the development and identification of ACPs are time-consuming and expensive in traditional wet-lab-based approaches. Thus, the application of artificial intelligence on the approaches can save time and reduce the cost to identify candidate ACPs. Recently, machine learning (ML), deep learning (DL), and hybrid learning (ML combined DL) have emerged into the development of ACPs without experimental analysis, owing to advances in computer power and big data from the power system. Additionally, we suggest that combination therapy with classical approaches and ACPs might be one of the impactful approaches to increase the efficiency of cancer therapy.

Verified
Journal Article
Open access
PDF file
DKDo Hyeon Kwon
Do Hyeon Kwon
JHJi Su Hwang
Ji Su Hwang
SKSeok Gi Kim
Seok Gi Kim
YJYong Eun Jang
Yong Eun Jang
TSTae Hwan Shin
Tae Hwan Shin
GLGwang Lee
Gwang Lee
Parkinson’s disease (PD) and multiple system atrophy (MSA) belong to the neurodegenerative group of synucleinopathies; differential diagnosis between PD and MSA is difficult, especially at early stages, owing to their clinical and biological similarities. Thus, there is a pressing need to identify metabolic biomarkers for these diseases. The metabolic profile of the cerebrospinal fluid (CSF) is reported to be altered in PD and MSA; however, the altered metabolites remain unclear. We created a single network with altered metabolites in PD and MSA based on the literature and assessed biological functions, including metabolic disorders of the nervous system, inflammation, concentration of ATP, and neurological disorder, through bioinformatics methods. Our in-silico prediction-based metabolic networks are consistent with Parkinsonism events. Although metabolomics approaches provide a more quantitative understanding of biochemical events underlying the symptoms of PD and MSA, limitations persist in covering molecules related to neurodegenerative disease pathways. Thus, omics data, such as proteomics and microRNA, help understand the altered metabolomes mechanism. In particular, integrated omics and machine learning approaches will be helpful to elucidate the pathological mechanisms of PD and MSA. This review discusses the altered metabolites between PD and MSA in the CSF and omics approaches to discover diagnostic biomarkers.

Verified
Journal Article
Open access
PDF file
SKSeok Gi Kim
Seok Gi Kim
JHJi Su Hwang
Ji Su Hwang
NGNimisha Pradeep George
Nimisha Pradeep George
YJYong Eun Jang
Yong Eun Jang
MKMinjun Kwon
Minjun Kwon
GLGwang Lee
Gwang Lee
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Recent studies have highlighted the significant role of cerebrospinal fluid (CSF) in reflecting pathophysiological PD brain conditions by analyzing the components of CSF. Based on the published literature, we created a single network with altered metabolites in the CSF of patients with PD. We analyzed biological functions related to the transmembrane of mitochondria, respiration of mitochondria, neurodegeneration, and PD using a bioinformatics tool. As the proteome reflects phenotypes, we collected proteome data based on published papers, and the biological function of the single network showed similarities with that of the metabolomic network. Then, we analyzed the single network of integrated metabolome and proteome. In silico predictions based on the single network with integrated metabolomics and proteomics showed that neurodegeneration and PD were predicted to be activated. In contrast, mitochondrial transmembrane activity and respiration were predicted to be suppressed in the CSF of patients with PD. This review underscores the importance of integrated omics analyses in deciphering PD’s complex biochemical networks underlying neurodegeneration.

20 June 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
YJYong Eun Jang
Yong Eun Jang
MKMinjun Kwon
Minjun Kwon
SKSeok Gi Kim
Seok Gi Kim
NGNimisha Pradeep George
Nimisha Pradeep George
JHJi Su Hwang
Ji Su Hwang
GLGwang Lee
Gwang Lee
Cell-penetrating peptides (CPPs) have gained significant attention for biomedical applications, including drug delivery and therapeutic development, due to their ability to penetrate cell membranes. The accurate prediction of CPPs is critical for accelerating the design and development of novel peptide-based therapies. Approaches for CPP prediction primarily depend on either peptide characteristic-based conventional features or one or two protein language models (PLMs), but these methods often fail to fully leverage the potential of combining diverse features. To address this limitation, we propose CPPpred-En, a prediction model that evaluates multiple conventional and PLM-based features across various machine learning classifiers, selects high-performing feature-classifier combinations, and integrates them through ensemble learning. The CPPpred-En model, which was trained on both the CPP924 and MLCPP 2.0 datasets, outperformed existing state-of-the-art predictors, achieving an accuracy (Acc) of 97.27 % and a matthews correlation coefficient (MCC) of 0.964 on the CPP924 dataset and an Acc of 96.10 % and an MCC of 0.707 on the MLCPP 2.0 dataset. The ensemble-based strategy demonstrated robustness across different datasets, highlighting the strong ability of the model to generalise. The combination of conventional and PLM features in an ensemble framework is promising approach for improving peptide-based therapeutics. The CPPpred-En model is a highly accurate and reliable tool for the identification of CPPs and their application in drug delivery and targeted therapy.

12 February 2025 in Cells
Verified
Journal Article
Open access
PDF file
NGNimisha Pradeep George
Nimisha Pradeep George
MKMinjun Kwon
Minjun Kwon
YJYong Eun Jang
Yong Eun Jang
SKSeok Gi Kim
Seok Gi Kim
JHJi Su Hwang
Ji Su Hwang
GLGwang Lee
Gwang Lee
Multiple system atrophy (MSA) is a progressive neurodegenerative synucleinopathy. Differentiating MSA from other synucleinopathies, especially in the early stages, is challenging because of its overlapping symptoms with other forms of Parkinsonism. Thus, there is a pressing need to clarify the underlying biological mechanisms and identify specific biomarkers for MSA. The metabolic profile of cerebrospinal fluid (CSF) is known to be altered in MSA. To further investigate the biological mechanisms behind the metabolic changes, we created a network of altered CSF metabolites in patients with MSA and analysed these changes using bioinformatic software. Acknowledging the limitations of metabolomics, we incorporated proteomic data to improve the overall comprehensiveness of the study. Our in silico predictions showed elevated ROS, cytoplasmic inclusions, white matter demyelination, ataxia, and neurodegeneration, with ATP concentration, neurotransmitter release, and oligodendrocyte count predicted to be suppressed in MSA CSF samples. Machine learning and dimension reduction are important multi-omics approaches as they handle large amounts of data, identify patterns, and make predictions while reducing variance without information loss and generating easily visualised plots that help identify clusters, patterns, or outliers. Thus, integrated multiomics and machine learning approaches are essential for elucidating neurodegenerative mechanisms and identifying potential diagnostic biomarkers of MSA.

3 July 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
MKMinjun Kwon
Minjun Kwon
YJYong Eun Jang
Yong Eun Jang
JHJi Su Hwang
Ji Su Hwang
SKSeok Gi Kim
Seok Gi Kim
NGNimisha Pradeep George
Nimisha Pradeep George
GLGwang Lee
Gwang Lee
Anticancer peptide (ACP) has emerged as potent therapeutic agents owing to its ability to selectively target cancer cells while minimising toxicity to healthy cells. However, the accurate computational prediction of ACP remains challenging because of the complex molecular mechanisms underlying cancer. In this study, we introduce EnsemPred-ACP, an innovative ensemble framework that combines machine learning (ML) and deep learning (DL) approaches to enhance ACP prediction. Our primary innovation is the introduction of binary profile features (BPF) to augment pre-trained protein embeddings, thereby capturing position-specific patterns crucial for ACP identification. The framework used a dual-pipeline architecture; ML models processed handcrafted sequence features and embeddings, whereas DL models handled BPF-enhanced embeddings. Upon evaluation with independent datasets, EnsemPred-ACP achieved an accuracy of 0.863, sensitivity of 0.897, and specificity of 0.830, notably outperforming existing methods. The model demonstrated a strong generalisation performance, achieving an area under the receiver operating characteristic curve of 0.93. Ablation studies on independent datasets further highlighted the substantial impact of BPF, enhancing the prediction accuracy by 2.5 % and 11.1 % when integrated with ESM2 and ProtT5 embeddings, respectively. These results demonstrate the effectiveness of our integrated approach in accurately identifying potential therapeutic peptides, thereby contributing to the advancement of peptide-based cancer therapeutics.